Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ...
ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients ...
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...
The global continuous peripheral nerve block catheter market is poised for significant growth, with revenues expected to rise from USD 585.6 million in 2023 to USD 1,058.6 million by 2033, ...
The global hepatitis B diagnostic tests market is on the cusp of substantial expansion, driven by a combination of increasing disease incidence, heightened global awareness campaigns, and rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback